Skip to main content
PMC home page
ESMO Open logoLink to ESMO Open
. 2022 Apr 22;7(3):100494. doi: 10.1016/j.esmoop.2022.100494

Corrigendum to ‘Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials’

[ESMO Open Volume 7, Issue 2, (2022), 100455]

D König 1,∗, S Schär 2, D Vuong 3, M Guckenberger 3, K Furrer 4, I Opitz 4, W Weder 5, SI Rothschild 1, A Ochsenbein 6, A Zippelius 1, A Addeo 7, M Mark 8, EI Eboulet 2, S Hayoz 2, S Thierstein 2, DC Betticher 9, H-B Ris 10, R Stupp 11, A Curioni-Fontecedro 12, S Peters 13, M Pless 14, M Früh 6,15
PMCID: PMC9051622  PMID: 35468561

The authors regret that an affiliation for M. Früh was missing. This should be as follows:

M. Früh6,15

  • 6Department of Medical Oncology, University Hospital of Bern (Inselspital), Bern, Switzerland

  • 15Department of Medical Oncology/Hematology, Cantonal Hospital of St. Gallen, St. Gallen, Switzerland

All other affiliations are correct.

The authors would like to apologise for any inconvenience caused.

RESOURCES